Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$0.65 USD
-0.01 (-1.38%)
Updated Nov 1, 2024 03:45 PM ET
After-Market: $0.63 -0.02 (-3.08%) 7:58 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Hepion Pharmaceuticals, Inc. (HEPA) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $30.00 | $30.00 | $30.00 | 4,445.45% |
Price Target
Only one analyst offered a short-term price target of $30.00 for Hepion Pharmaceuticals, Inc. This represents an increase of 4% from the last closing price of $0.66.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Hepion Pharmaceuticals, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | NA | NA |
| Buy | 0 | 0 | 0 | NA | NA |
| Hold | 0 | 0 | 0 | NA | NA |
| Sell | 0 | 0 | 0 | NA | NA |
| Strong Sell | 0 | 0 | 0 | NA | NA |
| ABR | 1.00 | 1.00 | 1.00 | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 9/15/2024 | Alliance Global Partners | James Molloy | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 1.00 |
| ABR (Last week) | 1.00 |
| # of Recs in ABR | 1 |
| Average Target Price | $30.00 |
| LT Growth Rate | NA |
| Industry | Medical - Biomedical and Genetics |
| Industry Rank by ABR | 89 of 252 |
| Current Quarter EPS Est: | NA |